H.R. 19: Lower Costs, More Cures Act of 2021
Before you vote › Federal bills
H.R. 19: Lower Costs, More Cures Act of 2021
117th Congress · introduced 2021-04-21 · Health · Latest: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
federal
Follow this bill, step by step
- Where it came from: introduced 2021-04-21 · official record
- Who proposed it: Rep. McMorris Rodgers, Cathy [R-WA-5] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
Lower Costs, More Cures Act of 2021
Plain summary
Lower Costs, More Cures Act of 2021 This bill establishes and modifies several programs and requirements to address prescription drug prices. The bill modifies provisions under Medicare and Medicaid relating to prescription drug coverage and price transparency. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; caps annual out-of-pocket spending under the Medicare prescription drug benefit; allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and allows states to include in the Medicaid Drug Rebate Program covered outpatient drugs that are provided as part of physician or outpatient hospital services. The bill also generally modifies other provisions relating to the regulation and costs of generic and brand-name drugs. Among other changes, the bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product; permanently allows high deductible health plans to waive deductibles for insulin and associated products; and establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
Lower Costs, More Cures Act of 2021
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. McMorris Rodgers, Cathy [R-WA-5] · 133 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Virginia Foxx (R-NC), Brett Guthrie (R-KY), Rick W. Allen (R-GA), Lloyd Smucker (R-PA), Dusty Johnson (R-SD), Richard Hudson (R-NC), David Schweikert (R-AZ), Andy Barr (R-KY), Ron Estes (R-KS), Earl L. "Buddy" Carter (R-GA), Robert E. Latta (R-OH), Gus M. Bilirakis (R-FL), John R. Carter (R-TX), Troy E. Nehls (R-TX), Jason Smith (R-MO), H. Morgan Griffith (R-VA), Vern Buchanan (R-FL), John R. Curtis (R-UT), Darin LaHood (R-IL), Ronny Jackson (R-TX), Beth Van Duyne (R-TX), Guy Reschenthaler (R-PA), Claudia Tenney (R-NY), Tim Burchett (R-TN), Ralph Norman (R-SC), Kevin Hern (R-OK), Ann Wagner (R-MO), Roger Williams (R-TX), Diana Harshbarger (R-TN), Daniel Meuser (R-PA), John Joyce (R-PA), Don Bacon (R-NE), Neal P. Dunn (R-FL), Dan Crenshaw (R-TX), Elise M. Stefanik (R-NY), Jodey C. Arrington (R-TX), Joe Wilson (R-SC), Tim Walberg (R-MI), W. Gregory Steube (R-FL), Stephanie I. Bice (R-OK), Pete Stauber (R-MN), Ashley Hinson (R-IA), David P. Joyce (R-OH) and 73 more.
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Words on this page, explained (2)
- Bill
- A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).
- Rulemaking
- The process agencies use to write regulations that carry out laws passed by Congress or a legislature. Usually an agency publishes a proposed rule, takes public comments, then publishes a final rule.
Plain meanings written from linked sources. All words.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-117hr19.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hr>
Record fed-us-cong117-hr19 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117